Literature DB >> 15034873

Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome.

Effie K Grand1, Francis H Grand, Andrew J Chase, Fiona M Ross, Martin M Corcoran, David G Oscier, Nicholas C P Cross.   

Abstract

The 8p11 myeloproliferative syndrome (EMS) is an aggressive hematological malignancy caused by the fusion of diverse partner genes to fibroblast growth factor receptor 1 (FGFR1). The partner proteins promote dimerization and ligand-independent activation of FGFR1-encoded tyrosine kinase, deregulating hemopoiesis in a manner analogous to BCR-ABL in chronic myeloid leukemia. Here, we describe the identification of a new FGFR1 fusion gene in a patient who presented with T-cell lymphoblastic lymphoma in conjunction with an acquired ins(12;8)(p11;p11p22). Initial FISH analysis and Southern blotting confirmed that FGFR1 was disrupted. Using 5'-RACE PCR, we identified part of a novel gene, FGFR1OP2, at chromosome band 12p11 that was fused to exon 9 of FGFR1.FGFR1OP2 is predicted to be translated into an evolutionarily conserved protein containing coiled-coil domains but no other recognizable motifs. The presence of the chimeric gene was confirmed by RT-PCR, genomic DNA PCR, and FISH. These data further support the central role of deregulated FGFR1 in the pathogenesis of EMS. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15034873     DOI: 10.1002/gcc.20023

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  23 in total

1.  FGFR1OP2-FGFR1 induced myeloid leukemia and T-cell lymphoma in a mouse model.

Authors:  Haiyan Qin; Qing Wu; John K Cowell; Mingqiang Ren
Journal:  Haematologica       Date:  2015-11-20       Impact factor: 9.941

Review 2.  STRIPAK complexes in cell signaling and cancer.

Authors:  Z Shi; S Jiao; Z Zhou
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

3.  Tiered assembly of the yeast Far3-7-8-9-10-11 complex at the endoplasmic reticulum.

Authors:  Tammy Pracheil; Zhengchang Liu
Journal:  J Biol Chem       Date:  2013-04-26       Impact factor: 5.157

4.  Wound closure and wound management: A new therapeutic molecular target.

Authors:  Audrey Lin; Akishige Hokugo; Ichiro Nishimura
Journal:  Cell Adh Migr       Date:  2010-07-31       Impact factor: 3.405

Review 5.  STRIPAK complexes: structure, biological function, and involvement in human diseases.

Authors:  Juyeon Hwang; David C Pallas
Journal:  Int J Biochem Cell Biol       Date:  2013-12-11       Impact factor: 5.085

6.  Neutralizing FGF4 protein in conditioned medium of IL-21-silenced HCT116 cells restores the migratory activity of the colorectal cancer cells.

Authors:  Eshtiyag Abdalla Abdalkareem; Ching Yi Ong; Boon Huat Lim; Boon Yin Khoo
Journal:  Cytotechnology       Date:  2018-05-25       Impact factor: 2.058

7.  The 8p12 myeloproliferative syndrome.

Authors:  O John-Olabode Sarahx; A Oyekunle Anthony; A Adeyemo Titilope; S Akanmu Alani
Journal:  Niger Med J       Date:  2014-03

8.  Small cytoskeleton-associated molecule, fibroblast growth factor receptor 1 oncogene partner 2/wound inducible transcript-3.0 (FGFR1OP2/wit3.0), facilitates fibroblast-driven wound closure.

Authors:  Audrey Lin; Akishige Hokugo; Jae Choi; Ichiro Nishimura
Journal:  Am J Pathol       Date:  2009-12-03       Impact factor: 4.307

9.  A PP2A phosphatase high density interaction network identifies a novel striatin-interacting phosphatase and kinase complex linked to the cerebral cavernous malformation 3 (CCM3) protein.

Authors:  Marilyn Goudreault; Lisa M D'Ambrosio; Michelle J Kean; Michael J Mullin; Brett G Larsen; Amy Sanchez; Sidharth Chaudhry; Ginny I Chen; Frank Sicheri; Alexey I Nesvizhskii; Ruedi Aebersold; Brian Raught; Anne-Claude Gingras
Journal:  Mol Cell Proteomics       Date:  2008-09-08       Impact factor: 5.911

10.  The 8p11 myeloproliferative syndrome: review of literature and an illustrative case report.

Authors:  Ami Goradia; Michael Bayerl; Dennis Cornfield
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.